SQZ Biotechnologies Company (SQZ)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

13.03-0.52 (-3.84%)

At close: 4:00PM EDT

13.03 -0.07 (-0.53%)
After hours: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	13.55
Open	13.66
Bid	12.98 x 800
Ask	13.09 x 1300
Day's Range	12.60 - 13.74
52 Week Range	11.53 - 36.49
Volume	127,321
Avg. Volume	184,409

Market Cap	363.143M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	37.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its next generation SQZ™ APCs, enhanced APCs or eAPCs, and the potentially broader applicability of the platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting.
- SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies
  GlobeNewswire
- OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD
  Business Wire
Business Wire
SQZ Biotech to Participate in April Investor Events
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in multiple investor conferences in April 2021. Armon Sharei, PhD, chief executive officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021 and will participate in a cell therapy focused panel at the Canaccord Horizons in Oncology Virtual Conference on April 15, 2021. The company will also be hosting one on one meetings at both conferences.
Simply Wall St.
Earnings Update: SQZ Biotechnologies Company (NYSE:SQZ) Just Reported And Analysts Are Trimming Their Forecasts
SQZ Biotechnologies Company ( NYSE:SQZ ) came out with its full-year results last week, and we wanted to see how the...